Antihyperglycemic Therapy

The Link Between Diabetes and CVD

DPP-4 Inhibitors Demonstrated CV Safety

SAVOR-TIMI 53, EXAMINE, and TECOS First Hospitalization for Heart Failure

Heart Failure in the SAVOR-TIMI 53 Trial

Saxagliptin and Alogliptin Risk for Heart Failure

ELIXA: Lixisenatide

LEADER: Liraglutide

SUSTAIN-6: Semaglutide*

Making Sense of the CVOT Data

DPP-4 Inhibitors and GLP-1 Receptor Agonists for T2D

Clinical Applicability of CVOT Data

Renal Glucose Handling

EMPA-REG OUTCOME: Empagliflozin Cardiovascular Outcomes and Death From Any Cause

Empagliflozin New FDA Indication and Patient Education

IRIS: Pioglitazone

Metformin As First-Line Therapy in Patients With T2D

Patient Case Study

2016 ESC Heart Failure Guidelines and ADA 2017 Update

Cardiologists and Endocrinologists Working Together to Lower HbA1c

Trends in Diabetes-Related Complications Among Adults With Diabetes, 1990-2010

Proposed Pleiotropic CV Effects of SGLT-2 Inhibitors

Proposed Pleiotropic CV Effects of GLP-1 Receptor Agonists

Closing Comments

Abbreviations

Abbreviations (cont)